On April 3, 2024 NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, reported that Frank Scholz, Ph.D., President and Chief Executive Officer will present at the upcoming 2024 Jefferies Radiopharma Innovation Summit (Press release, NorthStar Medical Radiostopes, APR 4, 2024, View Source [SID1234641806]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Date: April 11, 2024
Time: 3:35 – 4:05 p.m. EDT
Location: Jefferies Conference Center, NYC, New York

"2024 and the next several years are pivotal for NorthStar as we expand our capabilities in the rapidly growing radiopharmaceuticals industry," said Frank Scholz, Ph.D., President and Chief Executive Officer of NorthStar Medical Radioisotopes. "We believe the industry is on the cusp of a global paradigm shift in the development and commercialization of effective new radiotherapies, and we believe our ability to produce medical radioisotopes at scale, coupled with the build-out of our radiopharmaceutical contract development and manufacturing services (CDMO/CMO services) on the same campus can be a key catalyst of this change."

"Today we are routinely producing therapeutic copper-67 that is used in on-going clinical trials," Scholz continued, "and are poised to be one of the first commercial-scale producers of non-carrier-added (n.c.a.) actinium-225 globally. Our radiopharmaceutical R&D lab is busy with both PET diagnostics and therapeutics work where sponsors are experiencing useful results as they work to improve upon their formulations and processes. NorthStar is strongly positioned for continued rapid growth in key areas of our industry, and we look forward to sharing information about our plans and future with the investor community at the upcoming Jefferies Radiopharma Innovation Summit."

Dr. Scholz and Paul Estrem, Executive Vice President and Chief Financial Officer, will also be available during the conference for one-on-one meetings. Please reach out to your Jefferies representative to schedule.

On April 4, 2024 NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, reported that it will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas. The conference will be held in San Diego, April 5-10, 2024 (Press release, NanoString Technologies, APR 4, 2024, View Source [SID1234641805]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NanoString and its customers will showcase 110 posters and highlight its products in three oral presentations focusing on unique biological insights generated with its platforms. The abstracts that will be featured include 14 studies exploring spatial biology using the CosMx Spatial Molecular Imager (SMI), 46 studies powered by GeoMx Digital Spatial Profiler (DSP), and 59 studies exploring gene expression using the nCounter Analysis System.

"NanoString customers are using the highest plex protein and RNA spatial biology panels commercially available on cancer patient samples, making fundamental discoveries and answering key questions about patient response to advanced cancer therapies utilized today. These research contributions are changing our understanding of the underlying biology driving tumor growth and metastases, greatly accelerating the development of new therapeutic approaches," said Joseph Beechem, Ph.D., Chief Scientific Officer and Senior Vice President of Research and Development, NanoString Technologies. "The spatial biology revolution has arrived! These new biological insights will help the field evolve from treating cancer to curing cancer."

Nanostring Product Showcase in Theater B, April 9, 10:00-11:00 AM PT

Dr. Beechem will present NanoString’s spatial biology roadmap and highlight recent advancements in a talk entitled "Highest-Plex Spatial Multi-Omics – Eliminating the Blind Spots in Your Research." He will be joined by Arutha Kulasinghe, Ph. D. Senior Research Fellow and Leader of the Clinical-oMx Lab at the University of Queensland, who will speak on "Uncoupling pathways involved in immunotherapy resistance: insights from deep tissue profiling."
Oral presentations:

Sunday, April 7, 4:20-4:35 PM PT – Golnaz Morad, Ph. D., from MD Anderson Cancer Center will present, "Digital spatial profiling of metastatic brain tumors reveals association of the tumor microbiome with immune alterations in the tumor microenvironment." This study investigated the role of distinct microbial communities in metastatic brain tumors through metagenomic sequencing of stool and saliva samples, 16S rRNA gene sequencing of tumor samples and spatial transcriptome and proteome analysis using NanoString platforms. The spatially resolved NanoString work was able to unequivocally resolve intracellular versus extracellular bacterial signals, greatly expanding our understanding of the innate-immune mediated anti-bacterial response within the tumor microenvironment.
Monday, April 8, 4:05-4:20 PM PT – Jingyi Cao, Ph. D from Gene Lay Institute of Immunology and Inflammation, Brigham and Women’s Hospital and Harvard Medical School will present, "Therapy-associated remodeling of pancreatic cancer revealed by single-cell spatial transcriptomics and optimal transport analysis." This study utilizes high-plex single-cell spatial molecular imaging (NanoString’s CosMx 1K Cell Characterization Panel) to dissect treatment-remodeled multicellular neighborhoods and malignant-stroma cell interactions in primary resected human pancreatic cancer. It revealed IL-6 family signaling as a potential inducer of chemoresistance.
Tuesday, April 9, 3:50-4:05 PM PT – Isobelle Wall, Kings College London, will present, "Spatial transcriptomics delineates tumor heterogeneity in NACT triple-negative breast cancer." This study utilizes spatial transcriptomics to investigate the histological and molecular heterogeneity of triple-negative breast cancer pre- and post-neoadjuvant chemotherapy. It revealed potential chemo-resistant properties and spatially distinct immune cell compositions associated with treatment response.
NanoString team members will welcome customers at booth 331.

On April 4, 2024 Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, reported that it will present a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (AACR) (Free AACR Whitepaper) 2024 being held on April 5-10, 2024 (Press release, Egle Therapeutics, APR 4, 2024, View Source [SID1234641804]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the poster, entitled "EGL-001 is a novel immunocytokine designed to specifically target and disarm T regulatory cells in the tumor microenvironment".

Egle scientists present evidence that EGL-001, a CTLA-4 targeted IL-2 dominant negative mutein, selectively binds to T regulatory (Treg) cells and inhibits Treg IL-2 signaling.

The resulting reduction of Treg frequencies and functionality, as observed in ex vivo human tumor cultures and in vivo mouse models, promotes effector T cell responses. Accordingly, EGL-001 induces anti-tumor responses in combination with anti-PD-1 treatment in mouse models.

EGL-001 is the first drug candidate to emerge from Egle’s discovery platform, and it’s being developed for treatment of advanced solid tumors and to restore responsiveness to PD-1 inhibition.

Session Category: Immunology; Session Title: Immune Modulation with Cytokines; Session Date and Time: Tuesday Apr 9, 2024 9:00 AM – 12:30 PM; Location: Poster Section 4; Poster Board Number: 23 Published Abstract Number: 4079

On April 4, 2024 Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, reported that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m. ET (Press release, Arcellx, APR 4, 2024, View Source [SID1234641803]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of this discussion will be accessible from Arcellx’s website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.

On April 4, 2024 Medivir AB (Nasdaq Stockholm: MVIR) reported that the Annual Report for 2023 now is available at the company’s website: www.medivir.com (Press release, Medivir, APR 4, 2024, View Source [SID1234641801]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the fall of 2023, very promising data from the ongoing phase 1b/2a study with Medivir’s spearhead project fostrox in combination with Lenvima were presented. The combination has shown continued improved clinical benefit in patients with advanced primary liver cancer (HCC) and at ASCO (Free ASCO Whitepaper)-GI in January 2024, data were presented showing further increases in the proportion of patients achieving a clinically relevant reduction in their liver tumor and patients staying on treatment longer with stopped tumor growth. This attracted very strong interest and the data has improved further in the first quarter of 2024.

The clear clinical benefit and great medical need present an opportunity to accelerate the clinical development of fostrox with the ambition of becoming the first approved pharmaceutical therapy for the second-line treatment of HCC, a market worth ~$2.5 billion annually. These efforts to bring fostrox closer to potentially accelerated approval are Medivir’s absolute focus in the continued clinical development. In addition to fostrox, which is carried out by the company, several of the projects that Medivir has licensed out to partners will also enter the clinical phase in 2024.

This and much more can be found in Medivir’s Annual Report 2023, published today at the website;

View Source